Palvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 7,174 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins sold 7,174 shares of the stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total transaction of $935,202.64. Following the sale, the director directly owned 139,790 shares of the company’s stock, valued at $18,223,024.40. The trade was a 4.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Performance

PVLA stock opened at $122.58 on Thursday. The firm’s 50-day moving average price is $146.74 and its two-hundred day moving average price is $134.32. Palvella Therapeutics, Inc. has a 12-month low of $68.96 and a 12-month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts anticipate that Palvella Therapeutics, Inc. will post -6.40 earnings per share for the current fiscal year.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $246 price target. Despite lowering its earnings forecasts, the analyst’s target remains well above recent trading levels, indicating continued confidence in Palvella’s longer-term opportunity. HC Wainwright analyst coverage
• Neutral Sentiment: Management will participate in the Chardan 10th Annual Healthcare Conference on October 20. The fireside chat could provide updates on Palvella’s development programs for rare skin diseases and vascular anomalies, although no new clinical or regulatory information was announced. Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
• Negative Sentiment: HC Wainwright significantly reduced its projected earnings for 2027 through 2030. Estimates were cut to losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029, while the 2030 forecast was reduced to $5.82 from $19.10. The revisions suggest a slower path to profitability and likely contributed to the stock’s decline.
• Negative Sentiment: Director George Jenkins sold 20,326 shares worth approximately $2.69 million across October 12 and 13. The transactions reduced his direct ownership by roughly 13% overall. Both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which may lessen their significance, but the sizable insider selling can still weigh on investor sentiment. Palvella Therapeutics SEC insider transaction filing

Analysts Set New Price Targets

Several equities research analysts have weighed in on PVLA shares. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. HC Wainwright reduced their target price on Palvella Therapeutics from $270.00 to $246.00 and set a “buy” rating on the stock in a research note on Monday. Chardan Capital initiated coverage on Palvella Therapeutics in a report on Monday, September 21st. They set a “buy” rating and a $240.00 target price for the company. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $207.43.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PVLA. KBC Group NV bought a new position in shares of Palvella Therapeutics during the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $35,000. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $69,000. Quantbot Technologies LP bought a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $71,000. Finally, Arizona State Retirement System boosted its position in shares of Palvella Therapeutics by 30.9% in the 2nd quarter. Arizona State Retirement System now owns 2,765 shares of the company’s stock worth $423,000 after purchasing an additional 652 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.